Communiqués Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Temps réel estimé Cboe BZX Autres places de cotation 17:27:20 12/06/2024			Varia. 5j.	Varia. 1 janv.
7,955 ^USD	+5,50 %		-1,99 %	+201,92 %

03/06	SUMMIT THERAPEUTICS INC. : Stifel Nicolaus persiste à l'achat	ZM
03/06	Mise à jour sectorielle : Les actions du secteur de la santé sont stables en pré-marché lundi	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab	03/06	BU
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA	01/06	BU
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy	01/06	BU
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	31/05	BU
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China	30/05	BU
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024	01/05	BU
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024	24/04	BU
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors	11/04	BU
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum	10/04	BU
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	25/03	AQ
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024	22/03	BU
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024	14/03	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT	11/03	PR
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference	05/03	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT	03/03	PR
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	26/02	BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023	20/02	BU
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024	15/02	AQ
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024	14/02	BU
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference	08/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Communiqués

Filtres